Literature DB >> 15936550

PSA bounces after neoadjuvant androgen deprivation and external beam radiation: impact on definitions of failure.

Anthony L Zietman1, John P Christodouleas, William U Shipley.   

Abstract

PURPOSE: To determine the characteristics of prostate specific antigen (PSA) bounces after external beam radiation therapy (EBRT) with neoadjuvant androgen deprivation and their impact on definitions of biochemical failure. METHODS AND MATERIALS: Characteristics of bounce were calculated for all patients treated by EBRT with neoadjuvant androgen deprivation at our institution between 1992 and 1998 (preexclusion analysis). Calculations were repeated for the subgroup that satisfied additional inclusion/exclusion criteria (postexclusion analysis). The percentage of bounces scoring as false positives according to the ASTRO definition of biochemical failure was compared with those for three alternative definitions (Vancouver, Nadir-plus-two, and Nadir-plus-three) using McNemar's tests.
RESULTS: Thirty-nine percent (preexclusion cohort) and 56% (postexclusion cohort) of patients demonstrated a PSA bounce. Twenty percent (preexclusion analysis) and 25% (postexclusion analysis) of these bounces scored as biochemical failure according to the ASTRO definition. The Nadir-plus-three definition scored the smallest percentage of bounces as failure, but the difference between this definition and the ASTRO definition reached statistical significance in neither preexclusion nor postexclusion analyses (p >/= 0.070).
CONCLUSIONS: A substantial proportion of patients treated by EBRT with neoadjuvant deprivation experienced a PSA bounce. A large percentage of these bounces scored as biochemical failure according to the ASTRO definition. The Nadir-plus-three definition is less vulnerable to this bias.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15936550     DOI: 10.1016/j.ijrobp.2004.11.020

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

1.  Long-term outcomes of three-dimensional conformal radiation therapy combined with neoadjuvant hormonal therapy for Japanese patients with T1c-T2N0M0 prostate cancer.

Authors:  Takashi Mizowaki; Kenji Takayama; Yoshiki Norihisa; Masakazu Ogura; Tomomi Kamba; Takahiro Inoue; Yosuke Shimizu; Toshiyuki Kamoto; Osamu Ogawa; Masahiro Hiraoka
Journal:  Int J Clin Oncol       Date:  2011-10-05       Impact factor: 3.402

2.  Long-term outcomes of three-dimensional conformal radiation therapy combined with neoadjuvant hormonal therapy in Japanese patients with locally advanced prostate cancer.

Authors:  Masato Sakamoto; Takashi Mizowaki; Michihide Mitsumori; Kenji Takayama; Keisuke Sasai; Yoshiki Norihisa; Toshiyuki Kamoto; Eijiro Nakamura; Osamu Ogawa; Masahiro Hiraoka
Journal:  Int J Clin Oncol       Date:  2010-07-23       Impact factor: 3.402

Review 3.  Advances in imaging and in non-surgical salvage treatments after radiorecurrence in prostate cancer: what does the oncologist, radiotherapist and radiologist need to know?

Authors:  Giovanni Luca Gravina; Vincenzo Tombolini; Mario Di Staso; Pietro Franzese; Pierluigi Bonfili; Antonio Gennarelli; Leda Di Nicola; Carlo Masciocchi; Ernesto Di Cesare
Journal:  Eur Radiol       Date:  2012-07-14       Impact factor: 5.315

4.  Early observed transient prostate-specific antigen elevations on a pilot study of external beam radiation therapy and fractionated MRI guided high dose rate brachytherapy boost.

Authors:  Anurag K Singh; Peter Guion; Robert C Susil; Deborah E Citrin; Holly Ning; Robert W Miller; Karen Ullman; Sharon Smith; Nancy Sears Crouse; Denise J Godette; Bronwyn R Stall; C Norman Coleman; Kevin Camphausen; Cynthia Ménard
Journal:  Radiat Oncol       Date:  2006-08-16       Impact factor: 3.481

5.  Distinguishing prostate-specific antigen bounces from biochemical failure after low-dose-rate prostate brachytherapy.

Authors:  Cian Hackett; Sunita Ghosh; Ron Sloboda; Kevin Martell; Lanna Lan; Nadeem Pervez; John Pedersen; Don Yee; Albert Murtha; John Amanie; Nawaid Usmani
Journal:  J Contemp Brachytherapy       Date:  2014-09-05

6.  PSA bouncing after brachytherapy HDR and external beam radiation therapy: a study of 121 patients with minimum 5-years follow-up.

Authors:  Roman Makarewicz; Andrzej Lebioda; Joanna Terlikiewicz; Marta Biedka; Tomasz Wiśniewski
Journal:  J Contemp Brachytherapy       Date:  2009-07-17

7.  Comparison of biochemical failure rates between permanent prostate brachytherapy and radical retropubic prostatectomy as a function of posttherapy PSA nadir plus 'X'.

Authors:  Kamran A Ahmed; Brian J Davis; Lance A Mynderse; Jeffrey M Slezak; Eric J Bergstralh; Torrence M Wilson; C Richard Choo
Journal:  Radiat Oncol       Date:  2014-07-29       Impact factor: 3.481

8.  Prostate specific antigen bounce after intensity-modulated radiation therapy in an Asian population.

Authors:  Yu Guang Tan; Weber Lau Kam On; Hong Hong Huang; Terence Tan Wee Kiat
Journal:  Asian J Urol       Date:  2016-01-13

9.  Kinetics of Prostate-Specific Antigen after Carbon Ion Radiotherapy for Prostate Cancer.

Authors:  Narisa Dewi Maulany Darwis; Takahiro Oike; Hidemasa Kawamura; Masahiro Kawahara; Nobuteru Kubo; Hiro Sato; Yuhei Miyasaka; Hiroyuki Katoh; Hitoshi Ishikawa; Hiroshi Matsui; Yoshiyuki Miyazawa; Kazuto Ito; Kazuhiro Suzuki; Soehartati Gondhowiardjo; Takashi Nakano; Tatsuya Ohno
Journal:  Cancers (Basel)       Date:  2020-03-04       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.